There is some preclinical and early clinical evidence suggesting that the combination of PI3K/Akt inhibitors and immunotherapy agents such as PD-1/PD-L1 inhibitors may have synergistic effects, resulting in improved anti-tumour responses [181,182]. The gene discussed is AKT1; the disease is neoplasm.